GlassScriptPhysician profile
Sharda Bhasin
NPI 1871517763
$3,798.73
in general payments reported to CMS, 2019-2025
38 companies · $49.55 in 2025
The $49.55 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $844 · 2020: $317 · 2021: $714 · 2022: $567 · 2023: $741 · 2024: $566 · 2025: $49.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,356.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $943.55 | 2019-2025 | Liletta |
| Hologic Sales and Service, LLC | $221.26 | 2019-2023 | Aptima, Acessa Provu System |
| Exeltis, USA INC. | $186.52 | 2021-2025 | Slynd |
| Organon LLC | $176.93 | 2021-2024 | Nexplanon |
| Mayne Pharma Commercial LLC | $174.00 | 2021-2024 | |
| Becton, Dickinson and Company | $158.77 | 2019-2023 | Bd Onclarity |
| Myovant Sciences INC. | $157.96 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $154.37 | 2019-2024 | |
| Astellas Pharma US INC | $153.57 | 2019-2024 | Veozah |
| Agile Therapeutics, INC. | $133.54 | 2021-2024 | Twirla |
| Therapeuticsmd, INC. | $126.98 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $124.97 | 2023 | Myfembree |
| Allergan, INC. | $110.93 | 2019 | |
| Aspira Women'S Health INC | $109.03 | 2019-2024 | Ova1 |
| Coopersurgical, INC. | $104.21 | 2019-2023 | Paragard T 380a |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $94.27 | 2021-2024 | |
| Evofem Biosciences, INC. | $90.51 | 2022-2024 | Phexxi |
| Avion Pharmaceuticals | $85.75 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $49.92 | 2019 | |
| Cepheid | $45.66 | 2019 | |
| Shield Therapeutics INC | $44.69 | 2024 | |
| Baxter Healthcare | $39.04 | 2023 | Perclot |
| Merck Sharp & Dohme LLC | $33.74 | 2019 | |
| Ascend Therapeutics US, LLC | $33.18 | 2019-2023 | |
| Abbott Laboratories | $23.08 | 2021 | |
| Urovant Sciences INC | $23.03 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $22.92 | 2021 | |
| Novo Nordisk INC | $21.06 | 2023 | Wegovy |
| Pfizer INC. | $20.14 | 2022 | |
| Biogen, INC. | $17.05 | 2024 | |
| Mylan Pharmaceuticals INC. | $16.11 | 2019 | |
| Mission Pharmacal Company | $16.07 | 2020 | |
| Roche Diagnostics Corporation | $15.19 | 2021 | |
| Mycovia Pharmaceuticals, INC. | $15.15 | 2022 | |
| Ethicon US, LLC | $14.45 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.06 | 2023 | Seglentis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.97 | 2020 | |
| Exact Sciences Corporation | $13.10 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharda Bhasin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.